

### Personal details

Date of Birth and Gender	01/04/1953, Female
First and Last Names	<b>Rose Ann PADUA</b>
Country	France

### Current Position

VivAdju SAS Co-Founder, President and Company Scientific Officer (CSO),  
[roseann.padua@vivadju.com](mailto:roseann.padua@vivadju.com)  
 VivaVacs Ltd Co-Director,  
[roseann.padua@vivavacs.com](mailto:roseann.padua@vivavacs.com)  
 Institut National de la Santé et de la Recherche Médicale (INSERM) Emeritus Research Director,  
[rose-ann.padua@inserm.fr](mailto:rose-ann.padua@inserm.fr)

### Organization/Company

Code RNSR / RNSR code	Organisation	Laboratory	Unit code	Postcode	City/Town
201420724V	VIVADJU			75010	Paris
	VIVAVACS			CB2 1PH	Cambridge
	INSERM	Hematology	UMR-S1342 Group 6	75010	Paris

### Other activities

1992 - 1997	Editorial Board Member, Leukemia
1997 - 1998	Editorial Board Member, Haematologica
1998 - 2003	Euroworkshop on Animal Models organizer, European (EU) Framework 5
2002 - 2012	Technical Contract Holder, International Atomic Energy Agency (IAEA)
2002 & 2008	Faculty Member, European Hematology Association (EHA) on Animal Models
2004 - Present	Member of European Leukemia Network (ELN), EU Framework 6 (FP6), Past Co-Chair of the Novel Targets and Animal Models Working Party
2004	Session Organizer and session Chair, EHA Annual Congress, Amsterdam
2005	Co-Organizer of ELN (FP6) symposium within EHA, Amsterdam
2006	Co-Organizer of the 11th International Conference on Differentiation Therapy and Innovative Therapeutics (ICDT) in Oncology, Versailles, France
2006	Co-Organizer of ELN (FP6) symposium within the ICDT, Versailles Reviewer and Co-Chair of myelodysplastic syndromes (MDS) session at the American Society for Hematology (ASH), Florida, USA
2007	Reviewer for the ASH, New Orleans, USA
2008 - 2012	EU COST action (BM0801) on Translating genomic and epigenetic studies of MDS and acute myelogenous leukemia (AML). Chair of working Group on Novel therapies and Animal Models.
2008	Co-organizer of the Symposium on Molecular Pathogenesis of Leukemia: Insights and Challenges, Sept 16-18 <sup>th</sup> , Frankfurt.
2015-2023	Scientific Advisory Board/Scientific Program Committee member for the EHA (2016-2023)

#### Learned societies :

1980 - Present	Member, Genetical Society, UK
1991 - Present	Member, Emeritus Member since 2020, American Society for Haematology (ASH)
1992 - Present	Member, Emeritus Member since 2019, American Association for Cancer Research (AACR)
1995 - Present	Member, Emeritus Member since 2019, European Hematology Association (EHA)
1998 - Present	Member, MDS Foundation

**Teaching:**

1987 - 2001	Supervisor to post graduate students for PhD and MD in the UK degrees in the Departments of Haematology and Surgery (UWCM). 9 PhD (John Gow, David Hughes, Graham Carter, Andrew Baker, Susan Ridge, Angela Gallagher, Sharon Mckenna, John Holmes, Barbara Guinn), 1 MPhil (clinical)(Melissa Smith), 2 MCh (clinical) (Vijay Shukla, David Lewis) 1 MD (clinical) (Dominic Culligan) students.
1999 - 2002	Supervisor to Student (Macarena Robledo) for Diplôme de Recherche Spécialisée (DRSU) University Paris-Diderot (7)
1998 - 2019	Lecturer to Undergraduate and postgraduate Medical Students, University of Paris-Diderot (7)
2006 - 2014	Supervisor to 5 PhD students, (Marie Robin, Stephanie Beurlet, Carole Le Pogam, Petra Gorombei, Laura Guerenne)
2007 - 2019	Supervisor and Lecturer to 6 Masters students (Flore Sicre, Elena Bernasconi, Petra Gorombei, Laure Goursaud, Gaetan Domin, Claire Kappel)
2008 - 2019	Organizer of English course for Ecole Doctorale B2T and tutor

**Professional Experience**

Start	End	City/Town	Organization/Company	Title/Function
2023	Present	Paris	VivAdju SAS	Co-Founder, President &CSO
2021	Present	Cambridge	VivaVacs Ltd.	Co-Director
2019	Present	Paris	INSERM UMR-S1342 Group 6, Institut de la Recherche Saint-Louis (IRSL)	Emeritus Director of Research
2005	2018	Paris	INSERM UMR-S1131, IRSL	Head of team, INSERM Director of Research
2002	2005	London	Kings College	Honorary Senior Lecturer
2001	2005	London	Kings College Hospital National Health Service (NHS)	Head of team Minimal Residual Disease (MRD)
1998	2000	San Francisco	University of California San Francisco (UCSF)	Visiting Fulbright Fellow
1997	1999	Paris	University of Paris Diderot (UPD)	Associate Professor
1995	2005	Paris	Institut Universitaire d'Hematologie (IUH)	Visiting Investigator
1994	2001	Cardiff	University of Wales College of Medicine (UWCM)	Reader
1991	1994	Cardiff	University of Wales (UWCM)	Senior Lecturer
1987	2001	Cardiff	University of Wales (UWCM)	Honorary Consultant
1987	1991	Cardiff	University of Wales (UWCM)	Deputy Director of Leukaemia Research Fund (LRF) Preleukemia Unit
1983	1987	Oxted, Surrey	Marie Curie Research Institute	Staff Research Scientist
1981	1982	Glasgow	Beatson Institute for Cancer Research	Postdoctoral Fellow, Medical Research Council (MRC)
1979	1981	Edinburgh	Edinburgh University	Postdoctoral Fellow (MRC)

**Career interruption**

N/A

**Education**

1999: Habilitation de la Recherche, UPD (France)  
1980: PhD, Edinburgh University (UK)  
1976: BSc (Honours) Edinburgh University (UK)

**Scientific productions****Honors**

1994 - 1997	Independent Investigator, LRF Fellowship
1997 - 1999	Associate Professor, UPD, France with Christine Chomienne
1998 - 1999	Fulbright Cancer Fellowship, sabbatical with Nobel Laureate, Michael Bishop, UCSF
2009	Prix Paris-Diderot Innovation

### **Research Grants Held**

1986 - 1989	LRF jointly with Bob Williamson & Keith Johnson (St. Mary's, London). Project: The Complete Mapping of Human Chromosome 19: A feasibility Study. Research Assistant. <b>Total value: £60,000.</b>
1987 - 1992	LRF, jointly with Allan Jacobs (UWCM). Project: Oncogenes in Preleukaemic States. Senior Lecturer and 2 research assistants and consumables. <b>Total value: £400,000.</b>
1988	MRC, jointly with Ian Peake (Haematology Dept., UWCM) & David Wynford-Thomas (Pathology, UWCM), Purchase of DNA extractor. <b>Total value: £48,634.</b>
1988 - 1992	LRF jointly with Allan Jacobs (UWCM). Project: The Role and Regulation of Oncogenes in Preleukaemic states. Technician, Graduate student, 2 Part-time laboratory aides. <b>Total value: £153,000.</b>
1990 - 1991	LRF, jointly with Allan Jacobs (UWCM). Project: Investigation of the role of FMS mutations in leukaemogenesis. Research assistant. <b>Total value: £19,600.</b>
1990 - 1993	Cancer Research Campaign, jointly with Les Hughes (Surgery, UWCM). Project: The role of transforming sequences in human malignant melanoma. Clinical Research Fellow <b>Total value: £74,943.</b>
1990 - 1993	University of Wales. Project: Molecular mechanisms of leukaemia therapy. Studentship . <b>Total value: £20,500.</b>
1990 - 1991	LRF, jointly with Allan Jacobs (UWCM). Project: FMS abnormalities in preleukaemias and lymphomas. Studentship. <b>Total value: £20,130.</b>
1990 - 1992	Blood Research Fund (UWCM). Project: p53 abnormalities in preleukaemias and leukaemia. Studentship. <b>Total value: £18,000.</b>
1991 - 1996	LRF, jointly with Allan Jacobs (UWCM). Project: Genetic lesions in preleukaemias. Senior Lecturer, 3 research assistants, 3 technicians, ancillary staff, part-time secretary. <b>Total value: £1,097,173.</b>
1991 - 1994	LRF, jointly with Allan Jacobs (UWCM). Project: FMS abnormalities in preleukaemias. Research Assistant. <b>Total value: £74,790.</b>
1991 - 1994	LRF (UWCM). Project: Suppressor genes in preleukaemias and leukaemias. Gordon Pillar Studentship. <b>Total value: £42,000.</b>
1991 - 1992	Blood Research Fund (UWCM). Project: RAS and RAS-related proteins in normal and preleukaemic haemopoietic cells. Polish Clinical Research Fellow. 1992 <b>Total value £16,000.</b>
1992 - 1993	Blood Research Fund (UWCM). Project: FMS mutations in monocytic leukaemia. Polish Clinical Research Fellow. <b>Total value: £16,000.</b>
1993 - 1996	Blood Research Fund (UWCM). Project: RAS and RAS-related proteins in leukaemias. Studentship. <b>Total Value: £33,600.</b>
1994 - 1994	Welsh Scheme for the Development of Health and Social Research (UWCM). Project: Cloning and characterisation of putative novel retinoic acid receptor alpha fusions in leukaemias. Research Assistant. <b>Total value: £12,966.</b>
1994 - 1997	LRF (UWCM). Project: Genetic lesions in preleukaemias and leukaemias. Reader, 1 Postdoctoral Fellow, 1 technician. <b>Total value: £274,105.</b>
1995 - 1996	Leukaemia Research Appeal for Wales (LRAW, UWCM). Project: Cloning and characterisation of a novel retinoic acid receptor alpha/promyelocytic leukaemia zinc finger (RAR $\alpha$ /PLZF) fusions in chronic lymphocytic leukaemias. Research Assistant. <b>Total value: £23,992.</b>
1995 - 1996	Ligue Nationale Contre le Cancer (IUH). Project: Characterisation of RAR $\alpha$ and PLZF gene abnormalities in B-cell chronic lymphocytic leukaemias. Salary. <b>Total value: 100,000 FF.</b>
1996 - 1997	ARC, jointly with Christine Chomienne (IUH). Project: RAR $\alpha$ abnormalities in leukaemia. Consumables. <b>Total value: 100,000FF.</b>
1997 - 1999	UPD. Professeur Associé. <b>Total value: 800,000FF.</b>
1998 - 1999	Fulbright Cancer Fellowship (sabbatical with J. Michael Bishop). Gene targeted vaccine production in acute promyelocytic leukaemia. <b>Total value: £15,000.</b>
1997 - 1998	Welsh Bone Marrow Transplant Research Fund (sabbatical with J. Michael Bishop). Gene targeted vaccine production in acute promyelocytic leukaemia. For 1 year from 1 <sup>st</sup> April 1997.

**Total value: £54,743.**

- 1998 - 2000 LRF (UWCM). Project: The role of the promyelocytic leukaemia zinc finger (PLZF) gene in haemopoiesis: cloning and characterisation of PLZF rearrangements in B-cell malignancies. Postdoctoral Fellow. **Total value: £69,000**
- 1999 - 2000 INSERM Research Fellowship (with Dominique Charron). Gene targeted vaccine production in leukaemia. **Total value: 134,299FF.**
- 2000 - 2001 Fondation pour la Recherche Medicale (with Christine Chomienne). Salary. **Total value: 120,000FF.**
- 2000 - 2000 Welsh Bone Marrow Transplant Research Fund. Project: The Role Of The Promeleocytic Leukaemia Zinc Finger (Plzf) Protein In Haematopoiesis. Postdoctoral fellow. **Total value £5,000.**
- 2000 - 2000 LRF (UWCM). Project : The Role Of The Promeleocytic Leukaemia Zinc Finger (PLZF) Protein In Haematopoiesis. Postdoctoral Fellow. **Total value: £18,420.**
- 2000 - 2001 Welsh Bone Marrow Transplant Research Fund. Project: Gene targeted vaccination against leukaemia. Consumables. **Total value: £10,000.**
- 2001 - 2004 Kay Kendall Leukaemia Research Fund (Kings College London). Project: Animal models for gene targeted immunotherapy for leukaemia. Postdoctoral Fellow. **Total value: £170,000.**
- 2001 -2002 Eli Lilly International Foundation. Project: Animal models for gene targeted immunotherapy for leukaemia. Technician for maintenance of transgenic mice in Paris. **Total value: £43,000.**
- 2002 - 2003 Eli Lilly International Foundation. Project: Animal models of (pre)leukaemia: targets for therapy Postdoctoral Fellow for maintenance of transgenic mice in Paris.  
**Total value: approximately £50,000.**
- 2005 - 2008 Canceropole. Project: Adjuvanticity of ATRA. Consumables. **Total value 30,000 €.**
- 2005 - 2007 ARC: Animal Models of myeloid leukaemia. Consumables. **Total value: 20,000 €.**
- 2007 - 2009 Fondation de France: Project: Identification of therapeutic targets against tumour progression in vivo. Consumables. **Total Value 46,000 €.**
- 2010 -2012 ARC (IUH): Consumables. **Total value: 50,000 €**
- 2011 - 2013 Association Laurette Fugain: Mechanism of action of an immunotherapy approach using a new DNA adjuvant. Consumables. **Total value: 45,000 €.**
- 2013 - 2015 Ligue Contre le Cancer: Mechanism of action of an immunotherapy approach using a new adjuvant associated with retinoic acid. Consumables. **Total value: 40,000 €.**
- 2011 - 2014 Assistance Publique-Hopitaux de Paris (AP-HP). Translational contract to the necessary studies to bring the nonspecific DNA vaccine to clinical trial. Salary **Total value: 54,000 €.**
- 2011 - 2014 University of Paris 7 studentship. Mechanism of action of DNA vaccination by site directed mutagenesis. Salary **Total value 50,000 €.**
- 2011 - 2014 European Union Cancer stem cell studentship with Christine Chomienne. Targeting Leukemia stem cells of NRASD12/BCL-2 animal models of MDS/AML progression. Salary and consumables. **Total value: 217,000 €.**
- 2015 - 2017 ARC with Pierre Fenaux: Using two mouse models of MDS as preclinical models for the evaluation of new treatments. Consumables. **Total value: 50,000 €.**
- 2016 - 2018 Abbvie/Genentech Industrial contract: Efficacy of ABT-199 and MEK inhibitors in NRAS/BCL-2 mouse models of MDS/AML progression. Salary and consumables. **Total Value: \$198,852**
- 2023 - 2025 BPI France (VivAdju): Mechanism of action of VIV-001 in a model of breast cancer. Salary and consumables . **Total Value: 140,000 €.**
- 2024 - 2025 BPI France (VivAdju): Development of tools for immunosurveillance after treatment with adjuvant immunotherapy to prevent cancer relapse. Incubation by Paris Biotech Santé and consumables. **Total Value; 15,000 €.**

**Total of approximately 4 Million €**

**Over 135 publications in Peer Reviewed Journals H-index 37**

5 most relevant publications		Major contribution of this publication
I	Le Pogam C, Patel S, Gorombeï P, Guerenne L, Krief P, Bernasconi E, Tekin N, Sicre F, Schlageter M-E, Chopin M, Mathews V, West RR, PLA M, Fenaux P, Chomienne C, <b>Padua RA.</b> DNA-mediated immunotherapy induces immune responses and extends life-span in two different	This paper describes a novel DNA-based immunotherapy reagent, pVAX14 and its efficacy in two myeloid malignancies to increase survival, induce immune responses and reduce tumour burden. This data supports the second patent application granted in Europe, US and Canada

	mouse models of myeloid malignancies. <b>Oncotarget</b> (2015) 6:32494-508. PMID:26378812	
2	Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, <b>Padua RA</b> . DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukaemia mouse model. <b>Blood</b> (2010) 15:653-6. PMID:19965687	This paper provides immunological insights into the mechanism of action of a specific PML-RARA vaccine. Our results demonstrate that DNA vaccination in combination with ATRA confers the effective boosting of interferon—producing and cytotoxic T cells in the leukemic mice.
3	Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, <b>Padua RA</b> , Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. <b>Nature Medicine</b> (2009) 15:566-571. PMID:19363496	This paper describes a new technology using the NanoPro. This instrument identifies specific isoforms of proteins by resolving the proteins based in their isoelectric point. We used this technique to identify a MEK isoform dephosphorylated upon DNA vaccination (Ref 1)
4	Robin M, Andreu-Gallien J, Schlageter M-H, Bengoufa D, Guillemot I, Pokorna K, Robert C, Larghero J, Rousselot P, Raffoux E, Dombret H, Fenaux P, Pla M, Charron D, <b>Padua RA</b> , Chomienne C. Frequent antibody production against RAR $\alpha$ in both APL mice And patients. <b>Blood</b> (2006) 108:1972-1974. PMID: 16728697	This paper shows that patients in remission from APL 2 years after treatment have measurable anti-RARA antibodies. This shows that patients in remission can make immune responses. This is important as we propose to position pVAX14 at low disease burden to prevent relapse.
5	<b>Padua RA</b> , Larghero J, Robin M, le Pogam C, Schlageter M-H, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudder L, Triesserenc H, Carpentier A, Kogan S, Degos L, Pla M, Bishop M, Stevenson FK, Charron D, Chomienne C. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. <b>Nature Medicine</b> (2003) 9:1413-1417. PMID: 14566333	Specific DNA vaccine directed to the PML-RARA fusion in combination with ATRA rescued the leukemia from relapse and death in a mouse model of leukemia for it's 2-years lifespan; increases in CD4+ and CD8+ T-cell subsets and anti-RARA antibody responses were seen. Patent 1 granted in Europe, US & Japan

#### Valorization

1. Patent: April 2002 (EP 02 291 069.9) relating to "Combined DNA vaccine and biological modifiers for cancer therapy", inventors are Christine Chomienne, Rose Ann Padua and Dominique Charron. PCT extension filed April 2003 (PCT/IB03/01600), EU (BET 04P0891 European patent application N° 03717465.3, granted 2013, EP 1 496 937 B1) and Japan (granted 2011, no. JP 4,354,826). Part of the patent has been granted in the US No. 02291069.9, granted 2008 on PML-RARaFrC and ATRA in APL, no. US 7,381,710 and granted 2013 on defined immunogenic DNA in any cancer, Attorney docket No. PO8427USO1/B, confirmation no: 6468 US No. 8,673,870. Patent Abandoned 2015.
2. Patent filed 2009 in Europe (BET 08P1378) "Kanamycin antisense nucleic acid for the treatment of cancer". Inventors: Christine Chomienne & Rose Ann Padua. PCT filed in March 2010 (PCTEP2010/054039, EP 09 290 224.6) BET 11P2576 - US 13/258173. Granted in Europe and United States in 2015 and Canada in 2019.
3. VivAdju/INSERM patent filed in Europe in March 2023 (EP23305447.7), PCT filed in the US (September 2025) and EU (January 2026)(PCT/EP2024/058784). . "pVAX14 nucleic acid formulated with a nano-vehicle in combination with all-trans retinoic acid (ATRA) to activate immune responses". Inventors: Rose Ann Padua, Bruno Pitard, Christine Chomienne, Patricia Krief and Marika Pla.
4. VivAdju/INSERM patent filed in Europe in March 2023 (EP23305449.3). PCT filed in the US (September 2025) and EU (January 2026) (PCT/EP2024/058788). "Combination of pVAX14 and all-trans retinoic acid (ATRA) with immune checkpoint inhibitor for the treatment of cancer". Inventors: Rose Ann Padua, Bruno Pitard, Christine Chomienne, Patricia Krief and Marika Pla.

#### Private activity

Co-Founder and member of the SAB, VivAdju SAS Jan 2023, Incubated by Paris Biotech Santé (Nov 2022-Dec 2025)  
Co-Founder and Director of VivaVacs Ltd. Since January 2021.  
Co-Founder of Vivavacs SAS 2007-2013, Incubated by Paris Biotech Santé (2006-2009), Closed voluntarily in 2013.  
Winner of the OSEO 2008 "creation-development" competition. Project leader: Christine Chomienne

